LG to supply new antidiabetic agent to Turkey

Published: 2010-11-12 06:59:00

Updated: 2010-11-12 06:59:00

LG Life Sciences Ltd. has signed a contract with Turkey based NOBEL Ilac for the development and export for LC15-0444, an oral dipeptidyl peptidase IV (DPP IV) inhibitor, for the treatment of type II diabetes, said the pharmaceutical division of LG Group on November 10.

Under the agreement, LGLS will receive a technology transfer fee of $200 million and export the active pharmaceutical ingr...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.